Page 1 of 47
NR 565 FINAL EXAM — ADVANCED PHARMACOLOGY
FUNDAMENTALS CHAMBERLAIN 2026/2027 COMPLETE
(100) CURRENT TESTING QUESTIONS AND CORRECT
ANSWERS WITH DETAILED RATIONALES.
PHARMACOLOGY
Prepare for the Chamberlain NR 565 Final Exam — Advanced Pharmacology
Fundamentals with a focused study resource covering essential pharmacology
principles for advanced nursing practice. It supports review of drug classifications,
pharmacokinetics, pharmacodynamics, therapeutic effects, adverse reactions, and
safe medication management. Use the material to reinforce key concepts, improve
recall, and identify areas that may need additional review before the final exam. This
resource is best suited for Chamberlain University NR 565 students preparing for the
final exam and reviewing advanced pharmacology fundamentals.
MULTIPLE CHOICE.
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–
20)
Question 1:
The study of what the body does to a drug, including absorption, distribution,
metabolism, and excretion, is known as:
A) Pharmacodynamics
B) Pharmacokinetics
C) Pharmacotherapeutics
D) Pharmacogenomics
Answer: B) Pharmacokinetics
Rationale: Pharmacokinetics describes the movement of drugs through
the body over time, encompassing the four processes of absorption,
distribution, metabolism, and excretion (ADME). Pharmacodynamics (A)
is what the drug does to the body. Pharmacotherapeutics (C) is the
clinical application of drugs. Pharmacogenomics (D) is the study of
genetic influences on drug response.
, Page 2 of 47
Question 2:
Pharmacodynamics is defined as:
A) The study of drug absorption and distribution
B) The study of what the drug does to the body
C) The process of drug metabolism in the liver
D) The elimination of drugs from the body
Answer: B) The study of what the drug does to the body
Rationale: Pharmacodynamics examines the biochemical and physiologic
effects of drugs and their mechanisms of action at receptor sites. Options
A, C, and D describe components of pharmacokinetics.
Question 3:
A drug that binds to a receptor and produces a response that is less than that
of a full agonist, even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
D) Non-competitive antagonist
Answer: A) Partial agonist
Rationale: A partial agonist has lower efficacy than a full agonist. It binds
to and activates a receptor but cannot produce a maximal response, even
when all receptors are occupied. An inverse agonist (B) produces the
opposite effect, and antagonists (C, D) block receptor activation.
Question 4:
The half-life of a drug is defined as:
A) The time required for the drug to reach peak concentration
B) The time required for the drug concentration to decrease by 50%
C) The time required for the drug to be completely eliminated
D) The time required for the drug to be absorbed
, Page 3 of 47
Answer: B) The time required for the drug concentration to decrease by
50%
Rationale: Half-life (t½) is the time required for the plasma concentration
of a drug to decrease by 50%. It determines the dosing interval and the
time required to reach steady state (approximately 4–5 half-lives).
Question 5:
A 65-year-old male with cirrhosis is prescribed a medication that undergoes
extensive first-pass hepatic metabolism. The nurse practitioner understands
that the bioavailability of this medication will be:
A) Decreased due to reduced absorption from the GI tract
B) Increased due to reduced first-pass metabolism
C) Unchanged due to compensatory mechanisms
D) Decreased due to increased protein binding
Answer: B) Increased due to reduced first-pass metabolism
Rationale: In cirrhosis, first-pass hepatic metabolism is reduced due to
damaged hepatocytes and portosystemic shunting, leading to increased
bioavailability of drugs that normally undergo extensive first-pass
metabolism. This requires dose reduction to avoid toxicity.
Question 6:
Which of the following occurs during Phase I metabolism of drugs via the
CYP450 enzyme system?
A) Drugs are conjugated to increase water solubility
B) Drugs are oxidized, reduced, or hydrolyzed
C) Drugs are excreted unchanged
D) Drugs are bound to plasma proteins
Answer: B) Drugs are oxidized, reduced, or hydrolyzed
Rationale: Phase I metabolism involves oxidation, reduction, or
hydrolysis reactions, typically mediated by the CYP450 enzyme system.
, Page 4 of 47
These reactions prepare drugs for Phase II conjugation reactions. Option
A describes Phase II metabolism.
Question 7:
A CYP450 enzyme inhibitor would most likely cause:
A) Decreased drug levels and therapeutic failure
B) Increased drug levels and potential toxicity
C) No change in drug levels
D) Faster drug elimination
Answer: B) Increased drug levels and potential toxicity
Rationale: CYP450 inhibitors slow drug metabolism, leading to increased
serum concentrations of medications metabolized through that pathway,
which can result in toxicity. CYP450 inducers (A) cause decreased drug
levels.
Question 8:
Which of the following is an example of a CYP450 inhibitor?
A) Rifampin
B) Phenytoin
C) Carbamazepine
D) Ketoconazole
Answer: D) Ketoconazole
Rationale: Ketoconazole is a potent CYP450 inhibitor. Inhibitors decrease
metabolic activity, leading to increased serum concentrations of other
medications metabolized by that pathway. Rifampin (A), Phenytoin (B),
and Carbamazepine (C) are CYP450 inducers.
Question 9:
A drug with a narrow therapeutic index requires:
A) Less frequent monitoring
NR 565 FINAL EXAM — ADVANCED PHARMACOLOGY
FUNDAMENTALS CHAMBERLAIN 2026/2027 COMPLETE
(100) CURRENT TESTING QUESTIONS AND CORRECT
ANSWERS WITH DETAILED RATIONALES.
PHARMACOLOGY
Prepare for the Chamberlain NR 565 Final Exam — Advanced Pharmacology
Fundamentals with a focused study resource covering essential pharmacology
principles for advanced nursing practice. It supports review of drug classifications,
pharmacokinetics, pharmacodynamics, therapeutic effects, adverse reactions, and
safe medication management. Use the material to reinforce key concepts, improve
recall, and identify areas that may need additional review before the final exam. This
resource is best suited for Chamberlain University NR 565 students preparing for the
final exam and reviewing advanced pharmacology fundamentals.
MULTIPLE CHOICE.
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–
20)
Question 1:
The study of what the body does to a drug, including absorption, distribution,
metabolism, and excretion, is known as:
A) Pharmacodynamics
B) Pharmacokinetics
C) Pharmacotherapeutics
D) Pharmacogenomics
Answer: B) Pharmacokinetics
Rationale: Pharmacokinetics describes the movement of drugs through
the body over time, encompassing the four processes of absorption,
distribution, metabolism, and excretion (ADME). Pharmacodynamics (A)
is what the drug does to the body. Pharmacotherapeutics (C) is the
clinical application of drugs. Pharmacogenomics (D) is the study of
genetic influences on drug response.
, Page 2 of 47
Question 2:
Pharmacodynamics is defined as:
A) The study of drug absorption and distribution
B) The study of what the drug does to the body
C) The process of drug metabolism in the liver
D) The elimination of drugs from the body
Answer: B) The study of what the drug does to the body
Rationale: Pharmacodynamics examines the biochemical and physiologic
effects of drugs and their mechanisms of action at receptor sites. Options
A, C, and D describe components of pharmacokinetics.
Question 3:
A drug that binds to a receptor and produces a response that is less than that
of a full agonist, even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
D) Non-competitive antagonist
Answer: A) Partial agonist
Rationale: A partial agonist has lower efficacy than a full agonist. It binds
to and activates a receptor but cannot produce a maximal response, even
when all receptors are occupied. An inverse agonist (B) produces the
opposite effect, and antagonists (C, D) block receptor activation.
Question 4:
The half-life of a drug is defined as:
A) The time required for the drug to reach peak concentration
B) The time required for the drug concentration to decrease by 50%
C) The time required for the drug to be completely eliminated
D) The time required for the drug to be absorbed
, Page 3 of 47
Answer: B) The time required for the drug concentration to decrease by
50%
Rationale: Half-life (t½) is the time required for the plasma concentration
of a drug to decrease by 50%. It determines the dosing interval and the
time required to reach steady state (approximately 4–5 half-lives).
Question 5:
A 65-year-old male with cirrhosis is prescribed a medication that undergoes
extensive first-pass hepatic metabolism. The nurse practitioner understands
that the bioavailability of this medication will be:
A) Decreased due to reduced absorption from the GI tract
B) Increased due to reduced first-pass metabolism
C) Unchanged due to compensatory mechanisms
D) Decreased due to increased protein binding
Answer: B) Increased due to reduced first-pass metabolism
Rationale: In cirrhosis, first-pass hepatic metabolism is reduced due to
damaged hepatocytes and portosystemic shunting, leading to increased
bioavailability of drugs that normally undergo extensive first-pass
metabolism. This requires dose reduction to avoid toxicity.
Question 6:
Which of the following occurs during Phase I metabolism of drugs via the
CYP450 enzyme system?
A) Drugs are conjugated to increase water solubility
B) Drugs are oxidized, reduced, or hydrolyzed
C) Drugs are excreted unchanged
D) Drugs are bound to plasma proteins
Answer: B) Drugs are oxidized, reduced, or hydrolyzed
Rationale: Phase I metabolism involves oxidation, reduction, or
hydrolysis reactions, typically mediated by the CYP450 enzyme system.
, Page 4 of 47
These reactions prepare drugs for Phase II conjugation reactions. Option
A describes Phase II metabolism.
Question 7:
A CYP450 enzyme inhibitor would most likely cause:
A) Decreased drug levels and therapeutic failure
B) Increased drug levels and potential toxicity
C) No change in drug levels
D) Faster drug elimination
Answer: B) Increased drug levels and potential toxicity
Rationale: CYP450 inhibitors slow drug metabolism, leading to increased
serum concentrations of medications metabolized through that pathway,
which can result in toxicity. CYP450 inducers (A) cause decreased drug
levels.
Question 8:
Which of the following is an example of a CYP450 inhibitor?
A) Rifampin
B) Phenytoin
C) Carbamazepine
D) Ketoconazole
Answer: D) Ketoconazole
Rationale: Ketoconazole is a potent CYP450 inhibitor. Inhibitors decrease
metabolic activity, leading to increased serum concentrations of other
medications metabolized by that pathway. Rifampin (A), Phenytoin (B),
and Carbamazepine (C) are CYP450 inducers.
Question 9:
A drug with a narrow therapeutic index requires:
A) Less frequent monitoring
